Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 929

1.

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.

Masuda N, Inoue K, Nakamura R, Rai Y, Mukai H, Ohno S, Hara F, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Huang X, Iwata H.

Int J Clin Oncol. 2018 Nov 3. doi: 10.1007/s10147-018-1359-3. [Epub ahead of print]

PMID:
30392115
2.

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M.

N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20.

3.

Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.

Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, Masuda N, Verma S, Loi S, Colleoni M, Theall KP, Huang X, Liu Y, Bartlett CH.

Eur J Cancer. 2018 Oct 8;104:21-31. doi: 10.1016/j.ejca.2018.08.011. [Epub ahead of print]

PMID:
30308388
4.

Pharmacokinetics and toxicokinetics of d-serine in rats.

Hasegawa H, Masuda N, Natori H, Shinohara Y, Ichida K.

J Pharm Biomed Anal. 2019 Jan 5;162:264-271. doi: 10.1016/j.jpba.2018.09.026. Epub 2018 Sep 14.

PMID:
30268994
5.

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.

Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y.

Breast Cancer Res Treat. 2018 Sep 21. doi: 10.1007/s10549-018-4964-y. [Epub ahead of print]

PMID:
30242578
6.

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J.

Eur J Cancer. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18.

PMID:
30241001
7.

Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.

Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M.

Breast Cancer Res Treat. 2018 Dec;172(3):611-618. doi: 10.1007/s10549-018-4958-9. Epub 2018 Sep 7.

PMID:
30194511
8.

Configuration model for correlation matrices preserving the node strength.

Masuda N, Kojaku S, Sano Y.

Phys Rev E. 2018 Jul;98(1-1):012312. doi: 10.1103/PhysRevE.98.012312.

PMID:
30110768
9.

Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.

Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S.

Eur J Cancer. 2018 Sep;101:123-133. doi: 10.1016/j.ejca.2018.05.017. Epub 2018 Jul 25.

PMID:
30053671
10.

Severe panuveitis with relapsing polychondritis.

Masuda N, Nishikawa R, Ueda T, Ogata N.

Am J Ophthalmol Case Rep. 2018 Apr 20;11:3-5. doi: 10.1016/j.ajoc.2018.04.024. eCollection 2018 Sep.

11.

Case report of a dose-volume histogram analysis of rib fracture after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study.

Yoshida K, Otani Y, Nose T, Yoden E, Asahi S, Tsukiyama I, Dokiya T, Saeki T, Fukuda I, Sekine H, Kumazaki Y, Takahashi T, Kotsuma T, Masuda N, Nakashima K, Matsumura T, Nakagawa S, Tachiiri S, Moriguchi Y, Itami J, Oguchi M.

J Contemp Brachytherapy. 2018 Jun;10(3):274-278. doi: 10.5114/jcb.2018.76983. Epub 2018 Jun 30.

12.

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S.

Jpn J Clin Oncol. 2018 Sep 1;48(9):855-859. doi: 10.1093/jjco/hyy097.

PMID:
30020510
13.

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study.

Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M.

Breast Cancer (Auckl). 2018 Jul 5;12:1178223418786243. doi: 10.1177/1178223418786243. eCollection 2018.

14.

Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1600. [Epub ahead of print]

15.

Effect of ASP6432, a Novel Type 1 Lysophosphatidic Acid Receptor Antagonist, on Urethral Function and Prostate Cell Proliferation.

Sakamoto K, Noguchi Y, Ueshima K, Yamakuni H, Ohtake A, Sato S, Ishizu K, Hosogai N, Kawaminami E, Takeda M, Masuda N.

J Pharmacol Exp Ther. 2018 Aug;366(2):390-396. doi: 10.1124/jpet.118.247908. Epub 2018 Jun 8.

PMID:
29884626
16.

Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.

Nakahara Y, Fukui T, Shirasawa M, Harada S, Kusuhara S, Takakura A, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Masuda N, Inukai M, Sekiguchi T, Naoki K.

Intern Med. 2018 Nov 1;57(21):3149-3152. doi: 10.2169/internalmedicine.9884-17. Epub 2018 Jun 6.

17.

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation.

Niwa H, Nakahara Y, Sasaki J, Masuda N.

BMJ Case Rep. 2018 Jun 4;2018. pii: bcr-2017-219770. doi: 10.1136/bcr-2017-219770.

18.

Effect of DS-2969b, a novel GyrB inhibitor, on rat and monkey intestinal microbiota.

Kumar M, Mathur T, Joshi V, Upadhyay DJ, Inoue SI, Masuda N.

Anaerobe. 2018 Jun;51:120-123. doi: 10.1016/j.anaerobe.2018.04.017. Epub 2018 May 2.

PMID:
29758524
19.

A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor.

Dennie J, Vandell AG, Inoue S, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Uchiyama M, Yamada M, Senaldi G.

J Clin Pharmacol. 2018 Dec;58(12):1557-1565. doi: 10.1002/jcph.1151. Epub 2018 May 10.

PMID:
29746725
20.

A generalised significance test for individual communities in networks.

Kojaku S, Masuda N.

Sci Rep. 2018 May 9;8(1):7351. doi: 10.1038/s41598-018-25560-z.

21.

Population changes in residential clusters in Japan.

Sekiguchi T, Tamura K, Masuda N.

PLoS One. 2018 May 9;13(5):e0197144. doi: 10.1371/journal.pone.0197144. eCollection 2018.

22.

A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.

Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M.

Cancer Med. 2018 Jun;7(6):2442-2451. doi: 10.1002/cam4.1516. Epub 2018 May 7.

23.

Efficacy of Testosterone Treatment in Hemodialysis Patients as Assessed by Aging Males' Symptoms Scores: A Pilot Study.

Inoue Y, Nakamura K, Kuwahara Y, Lu Y, Masuda N, Horie S, Okada H, Ide H.

Am J Mens Health. 2018 Sep;12(5):1541-1547. doi: 10.1177/1557988318772734. Epub 2018 May 3.

24.

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report.

Niwa H, Otani S, Nakada N, Sasaki J, Saka H, Masuda N.

Respir Med Case Rep. 2018 Feb 2;23:131-135. doi: 10.1016/j.rmcr.2018.01.006. eCollection 2018.

25.

A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.

Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M.

PLoS One. 2018 Apr 3;13(4):e0195316. doi: 10.1371/journal.pone.0195316. eCollection 2018.

26.

In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus.

Barman TK, Kumar M, Mathur T, Namba E, Singh D, Chaira T, Kurosaka Y, Yamada M, Upadhyay DJ, Masuda N.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02556-17. doi: 10.1128/AAC.02556-17. Print 2018 Jun.

PMID:
29610202
27.

Development of copper recovery process from flotation tailings by a combined method of high‒pressure leaching‒solvent extraction.

Han B, Altansukh B, Haga K, Stevanović Z, Jonović R, Avramović L, Urosević D, Takasaki Y, Masuda N, Ishiyama D, Shibayama A.

J Hazard Mater. 2018 Jun 15;352:192-203. doi: 10.1016/j.jhazmat.2018.03.014. Epub 2018 Mar 19.

PMID:
29609151
28.

Clustering Coefficients for Correlation Networks.

Masuda N, Sakaki M, Ezaki T, Watanabe T.

Front Neuroinform. 2018 Mar 15;12:7. doi: 10.3389/fninf.2018.00007. eCollection 2018.

29.

Contamination trends and factors affecting the transfer of hexabromocyclododecane diastereomers, tetrabromobisphenol A, and 2,4,6-tribromophenol to breast milk in Japan.

Fujii Y, Kato Y, Masuda N, Harada KH, Koizumi A, Haraguchi K.

Environ Pollut. 2018 Jun;237:936-943. doi: 10.1016/j.envpol.2018.03.015. Epub 2018 Mar 20.

PMID:
29572047
30.

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.

Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M.

ESMO Open. 2018 Feb 14;3(2):e000314. doi: 10.1136/esmoopen-2017-000314. eCollection 2018.

31.

Age-related changes in the ease of dynamical transitions in human brain activity.

Ezaki T, Sakaki M, Watanabe T, Masuda N.

Hum Brain Mapp. 2018 Jun;39(6):2673-2688. doi: 10.1002/hbm.24033. Epub 2018 Mar 9.

PMID:
29524289
32.

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.

Ikeda S, Kato T, Ogura T, Sekine A, Oda T, Masuda N, Igawa S, Katono K, Otani S, Yamada K, Saito H, Kondo T, Hosomi Y, Nakahara Y, Nishikawa M, Utumi K, Misumi Y, Yamanaka T, Sakamaki K, Okamoto H.

BMC Cancer. 2018 Mar 2;18(1):241. doi: 10.1186/s12885-018-4150-y.

33.

Fragment-Based Discovery of Pyrimido[1,2-b]indazole PDE10A Inhibitors.

Chino A, Seo R, Amano Y, Namatame I, Hamaguchi W, Honbou K, Mihara T, Yamazaki M, Tomishima M, Masuda N.

Chem Pharm Bull (Tokyo). 2018;66(3):286-294. doi: 10.1248/cpb.c17-00836.

34.

Evaluation of the metabolic capability of primary human hepatocytes in three-dimensional cultures on microstructural plates.

Koyama S, Arakawa H, Itoh M, Masuda N, Yano K, Kojima H, Ogihara T.

Biopharm Drug Dispos. 2018 Apr;39(4):187-195. doi: 10.1002/bdd.2125. Epub 2018 Mar 13.

PMID:
29469947
35.

Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).

Nakayama T, Sagara Y, Takashima T, Matsunami N, Masuda N, Miyoshi Y, Taguchi T, Aono T, Ito T, Kagimura T, Noguchi S.

Cancer Chemother Pharmacol. 2018 Apr;81(4):755-762. doi: 10.1007/s00280-018-3544-5. Epub 2018 Feb 21.

36.

Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer.

Masuda N, Ogawa O, Park M, Liu AY, Goodison S, Dai Y, Kozai L, Furuya H, Lotan Y, Rosser CJ, Kobayashi T.

Oncotarget. 2018 Jan 3;9(6):7101-7111. doi: 10.18632/oncotarget.23872. eCollection 2018 Jan 23.

37.

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial.

Masuda N, Toi M, Yamamoto N, Iwata H, Kuroi K, Bando H, Ohtani S, Takano T, Inoue K, Yanagita Y, Kasai H, Morita S, Sakurai T, Ohno S.

Breast Cancer. 2018 Jul;25(4):407-415. doi: 10.1007/s12282-018-0839-7. Epub 2018 Feb 14.

38.

Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.

Vandell AG, Inoue S, Dennie J, Nagasawa Y, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Senaldi G.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02537-17. doi: 10.1128/AAC.02537-17. Print 2018 May.

39.

In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile.

Mathur T, Barman TK, Kumar M, Singh D, Kumar R, Khera MK, Yamada M, Inoue SI, Upadhyay DJ, Masuda N.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02157-17. doi: 10.1128/AAC.02157-17. Print 2018 Apr.

40.

In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens.

Purnapatre KP, Rao M, Pandya M, Khanna A, Chaira T, Bambal R, Upadhyay DJ, Masuda N.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01987-17. doi: 10.1128/AAC.01987-17. Print 2018 Apr.

41.

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).

Ohtani S, Nakayama T, Yoshinami T, Watanabe KI, Hara F, Sagara Y, Kawaguchi H, Higaki K, Matsunami N, Hasegawa Y, Takahashi M, Mizutani M, Morimoto T, Sato M, Itoh M, Morita S, Masuda N.

Breast Cancer. 2018 Jul;25(4):438-446. doi: 10.1007/s12282-018-0843-y. Epub 2018 Feb 12.

42.

Basigin expression as a prognostic indicator in stage I pulmonary adenocarcinoma.

Matsumoto T, Nagashio R, Ryuge S, Igawa S, Kobayashi M, Fukuda E, Goshima N, Ichinoe M, Jiang SX, Satoh Y, Masuda N, Murakumo Y, Saegusa M, Sato Y.

Pathol Int. 2018 Apr;68(4):232-240. doi: 10.1111/pin.12646. Epub 2018 Feb 12.

PMID:
29431238
43.

Sampling of temporal networks: Methods and biases.

Rocha LEC, Masuda N, Holme P.

Phys Rev E. 2017 Nov;96(5-1):052302. doi: 10.1103/PhysRevE.96.052302. Epub 2017 Nov 1.

PMID:
29347767
44.

Finding multiple core-periphery pairs in networks.

Kojaku S, Masuda N.

Phys Rev E. 2017 Nov;96(5-1):052313. doi: 10.1103/PhysRevE.96.052313. Epub 2017 Nov 22.

PMID:
29347658
45.

Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.

Masuda N, Nishimura R, Takahashi M, Inoue K, Ohno S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Toi M.

Cancer Sci. 2018 Mar;109(3):803-813. doi: 10.1111/cas.13507. Epub 2018 Feb 22.

46.

Capecitabine for primary breast cancer.

Toi M, Masuda N, Lee SJ.

Oncotarget. 2017 Dec 6;8(67):110739-110740. doi: 10.18632/oncotarget.22990. eCollection 2017 Dec 19. No abstract available.

47.

Ultrastructural and Immunohistochemical Study on the Lamina Propria Cells Beneath Paneth Cells in the Rat Ileum.

Mantani Y, Nishida M, Yamamoto K, Miyamoto K, Yuasa H, Masuda N, Omotehara T, Tsuruta H, Yokoyama T, Hoshi N, Kitagawa H.

Anat Rec (Hoboken). 2018 Jun;301(6):1074-1085. doi: 10.1002/ar.23778. Epub 2018 Jan 18.

PMID:
29316348
48.

Immunohistochemical study on the distribution of β-defensin 1 and β-defensin 2 throughout the respiratory tract of healthy rats.

Masuda N, Mantani Y, Yuasa H, Yoshitomi C, Arai M, Nishida M, Qi WM, Kawano J, Yokoyama T, Hoshi N, Kitagawa H.

J Vet Med Sci. 2018 Mar 24;80(3):395-404. doi: 10.1292/jvms.17-0686. Epub 2018 Jan 1.

49.

Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer.

Sugie T, Suzuki E, Yamauchi A, Yamagami K, Masuda N, Gondo N, Sumi E, Ikeda T, Tada H, Uozumi R, Kanao S, Tanaka Y, Hamazaki Y, Minato N, Toi M.

Breast. 2018 Apr;38:114-119. doi: 10.1016/j.breast.2017.12.017. Epub 2018 Jan 5.

PMID:
29310035
50.

Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.

Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, Oshitanai R, Tsuneizumi M, Watanabe KI, Matsui A, Fujisawa T, Saji S, Masuda N, Tokuda Y, Iwata H.

Oncotarget. 2017 Oct 27;8(61):103671-103681. doi: 10.18632/oncotarget.22110. eCollection 2017 Nov 28.

Supplemental Content

Loading ...
Support Center